Biotech News

CG Oncology to Present at Upcoming Investor Conferences in May

CG Oncology, Inc. (CGON)CG Oncology, Inc.Conference / presentation

CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will participate in fireside chat presentations at the Bank of America Health Care Conference and the RBC Capital Markets Global Healthcare Conference this month. The details of the upcoming events are as follows:

Bank of America Health Care Conference 2026 Date: Tuesday, May 12, 2026 Presentation Time: 10:40 AM – 11:10 AM PT Location: Las Vegas, NV

RBC Capital Markets Global Healthcare Conference Date: Wednesday, May 20, 2026 Presentation Time: 2:35 PM – 3:00 PM ET Location: New York, NY

Interested parties may access the live audio webcast for the conferences from the Investor Relations section of the company's website at www.cgoncology.com . The webcast replays will be available shortly after the conclusion of the live presentations and archived for approximately 90 days.

About CG Oncology CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

Contacts Media Sarah Connors Vice President, Communications and Patient Advocacy, CG Oncology sarah.connors@cgoncology.com

Investor Relations Megan Knight Vice President, Investor Relations, CG Oncology megan.knight@cgoncology.com

Related news

CG Oncology, Inc.

Bladder-Cancer Immunotherapy CG Oncology develops oncolytic immunotherapies for bladder cancer. Its lead candidate is administered directly into the bladder to selectively replicate in tumor cells and stimulate an antitumor immune response. Cretostimogene Grenadenorepvec Cretostimogene has been studied across more than 600 patients with...

Recent company news

Stock data

Close
79.81 USD
Market cap
4.9B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States